CAJ | 학술논문

目的：分析伊立替康联合铂类方案应用于初治及复发小细胞肺癌（small cell lung cancer，SCLC）患者的疗效及不良反应。方法52例初治广泛期 SCLC 患者中，采用伊立替康联合顺铂方案（IP 组）52例，同期复发的 SCLC 患者50例采用伊立替康联合奈达铂方案（IN 组），两组均至少进行2周期的化疗。分析比较两组疗效及不良反应。结果 IP 组客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）、1年及2年生存率明显优于 IN 组，腹泻发生率明显高于IN 组，差异均有统计学意义（P ＜0．05）。结论伊立替康联合铂类方案在初治及复治 SCLC 中疗效较好，初治方案好于复治方案，不良反应均可耐受，值得临床进一步推广。
목적：분석이립체강연합박류방안응용우초치급복발소세포폐암（small cell lung cancer，SCLC）환자적료효급불량반응。방법52례초치엄범기 SCLC 환자중，채용이립체강연합순박방안（IP 조）52례，동기복발적 SCLC 환자50례채용이립체강연합내체박방안（IN 조），량조균지소진행2주기적화료。분석비교량조료효급불량반응。결과 IP 조객관완해솔（ORR）、질병공제솔（DCR）、무진전생존기（PFS）、총생존기（OS）、1년급2년생존솔명현우우 IN 조，복사발생솔명현고우IN 조，차이균유통계학의의（P ＜0．05）。결론이립체강연합박류방안재초치급복치 SCLC 중료효교호，초치방안호우복치방안，불량반응균가내수，치득림상진일보추엄。
Objective To observe the efficacy and safety of irinotecan combined with platinum in the initial and recurrent treatment of small cell lung cancer (SCLC).Methods Fifty-two patients with previously-untreated extensive-stage SCLC were treated with a regimen of irinotecan and cisplatin (IP) for at least two cycles.Fifty recurrencent SCLC patients were treated with a regiment of irinotecan and nedaplatin (IN).The efficacy and toxicity were evaluated after the treatment .Results For the initial treatment of pa-tients,the overall response rate (ORR),disease control rates (DCR),the median PFS,median OS,one-year and two-year survival rate was significant higher than that in the IN group ,meanwhile,the diarrhea incidence was obviously higher than that in the IN group (P <0.05).Conclusion Regimen of irinotecan plus platinum is effective and tolerable in the initial and recurrent treatment of SCLC .The IP regimen is better than the IN regimen .